GRAYBUG VISION INC (GRAY) Stock Price, Forecast & Analysis
NASDAQ:GRAY • US38942Q1031
GRAY Key Statistics, Chart & Performance
The current stock price of GRAY is 5.5 USD. In the past month the price decreased by -37.39%. In the past year, price decreased by -69.78%.
GRAY Technical Analysis
GRAY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GRAY. While GRAY seems to be doing ok healthwise, there are quite some concerns on its profitability.
GRAY Financial Highlights
Over the last trailing twelve months GRAY reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS increased by 1.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
GRAY Forecast & Estimates
6 analysts have analysed GRAY and the average price target is 42.84 USD. This implies a price increase of 678.91% is expected in the next year compared to the current price of 5.5.
GRAY Ownership
GRAY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.36 | 994.53B | ||
| JNJ | JOHNSON & JOHNSON | 21.34 | 598.542B | ||
| MRK | MERCK & CO. INC. | 22.44 | 307.324B | ||
| PFE | PFIZER INC | 9.08 | 157.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.23 | 126.97B | ||
| ZTS | ZOETIS INC | 18.75 | 57.775B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.1 | 26.674B | ||
| VTRS | VIATRIS INC | 6.15 | 17.196B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.08 | 13.117B | ||
| AXSM | AXSOME THERAPEUTICS INC | 205.08 | 8.262B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRAY
Company Profile
Graybug Vision Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Redwood City, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The firm's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The firm is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.
Company Info
GRAYBUG VISION INC
274 Redwood Shores Parkway, P.O. Box 144
Redwood City CALIFORNIA 94065 US
CEO: Frederic Guerard
Employees: 8
Phone: 16504872800.0
GRAYBUG VISION INC / GRAY FAQ
Can you describe the business of GRAYBUG VISION INC?
Graybug Vision Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Redwood City, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The firm's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The firm is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.
Can you provide the latest stock price for GRAYBUG VISION INC?
The current stock price of GRAY is 5.5 USD. The price decreased by -10.8% in the last trading session.
Does GRAYBUG VISION INC pay dividends?
GRAY does not pay a dividend.
What is the ChartMill technical and fundamental rating of GRAY stock?
GRAY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is GRAY stock listed?
GRAY stock is listed on the Nasdaq exchange.
Who owns GRAYBUG VISION INC?
You can find the ownership structure of GRAYBUG VISION INC (GRAY) on the Ownership tab.